期刊文献+

氨氯地平降压疗效与L型钙离子通道α1C亚基的基因多态性的关系 被引量:11

Relationship of the genetic polymorphisms of L-type calcium channel α 1C gene and efficacy of amlodipine in the treatment of essential hypertension
原文传递
导出
摘要 目的研究氨氯地平的降压疗效与L型钙离子通道α1C亚基的基因(CACNA1C)单核苷酸多态性(SNPs)间的关联。方法纳入181例服用氨氯地平的原发性高血压患者,用PCR-直接测序法,对CACNA1C基因单核苷酸多态性(SNPs)rs1051375、rs2238032、rs7311382、rs2239050、rs2239127、rs2239128和rs2239129等位点进行基因分型;用多元线性回归方法,分析SNPs位点基因型与氨氯地平降压疗效间的关系。结果调整基线血压、体质量指数、血脂异常、性别和年龄的影响后,rs2238032G/T位点基因多态性与氨氯地平的降压疗效明显相关(△SBP:P=0.02;△DBP:P=0.01);rs1051375A/G、rs7311382C/T、rs2239050G/C、rs2239127C/T、rs2239128C/T和rs2239129C/T位点虽均显示出基因型间氨氯地平降压疗效的差异,但均无统计学意义(P>0.05)。结论 CAC-NA1C基因rs2238032位点基因多态性与原发性高血压患者服用氨氯地平的降压效果明显相关。 Objective To study association between genetic polymorphisms of L-type calcium channel alpha subunit 1C gene(CACNA1C) and efficacy of amlodipine in the treatment of hypertension.Methods A pharmacogenetic analysis was performed on 181 Chinese individuals with essential hypertension who were treated with amlodipine based antihypertensive drugs.Seven SNPs(rs1051375,rs2238032,rs7311382,rs2239050,rs2239127,rs2239128,rs2239129) in CACNA1C were chosen for genotypic analysis using direct sequencing method.Multiple linear regression was used to association analysis between genetic polymorphisms and efficacy of amlodipine.Results After adjustments of the influence of confounding factors on blood pressure,the comparison of 4th week′s △SBP and △DBP over genotypes of these single nucleotide polymorphisms showed that rs2238032G/T had a more significant association with BP reduction after treatments(△SBP:P=0.02;△DBP:P=0.01).Both SBP and DBP were significantly decreased in patients with TT+GT carrier in rs2238032 G/T when compared with patients with GG carrier.And rs2239050C/G,rs7311382C/T,rs2239127C/T,rs2239128C/T,rs2239129C/T,rs1051375A/G showed a significant difference in BP reduction over genotypes respectively.Conclusion SNPs rs2238032 in CACNA1C are associated with efficacy of amodipine in the treatment of essential hypertension.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2012年第1期8-12,共5页 The Chinese Journal of Clinical Pharmacology
基金 国家“重大新药创制”科技重大专项基金资助项目(2008ZX09312-018) 国家“十一五”科技支撑计划课题基金资助项目(2006BAI01A03)
关键词 CACNAIC基因 单核苷酸多态性 高血压 氨氯地平 L-type calcium channel alpha subunit 1C gene single nucleotide polymorphisms essential hypertension amlodipine
  • 相关文献

参考文献11

  • 1王文,成云芳,刘力生.中国北京上海广州门诊高血压患者脑卒中风险评估[J].中华高血压杂志,2007,15(z1):14-20. 被引量:16
  • 2张伦.氨氯地平市场浅析[J].中国药房,2006,17(6):413-415. 被引量:3
  • 3王文,马丽媛,刘明波,邓卿,张宇清,李卫,朱鼎良,林曙光,黄峻,刘力生.初始低剂量氨氯地平加替米沙坦或复方阿米洛利联合治疗对高血压患者血压控制率影响的阶段报告[J].中华心血管病杂志,2009,37(8):701-707. 被引量:86
  • 4Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or andodipine : the VALUE randomised trial [ J ]. Lancet, 2004; 363:2022 - 2031.
  • 5Johnson AD, Newton -Cheh C, Chasman DI, et al. Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals[ J ]. Hypertension ,2011 ; 57:903 - 910.
  • 6Bremer T, Man A, Kask K, et al. CACNAIC polymorphisms are associated with the efficacy of calcium channel blockers in the treat- ment of hypertension [ J ]. Pharmacogenomics,2006 ; 7:271 - 279.
  • 7Kamide K, Yang J, Matayoshi T, et al. Genetic polymorphisms of L- type calcium channel alphalC and alphal D subunit genes are associated with sensitivity to the antihypertensive effects of L - type dihydropyridine calcium - channel blockers [ J ]. Circ J, 2009 ; 73 : 732 - 740.
  • 8Beitelshees AL, Navare H, Wang D, et al. CACNAIC gene polymorphisms, cardiovascular disease outcomes, and treatment response[J]. Circ Cardiovasc Genet, 2009 ; 2:362 - 370.
  • 9俞蔚,唐新华,王文,徐小玲,章一丰,方顺元,周爱芬,王苏英,傅胜文,韩丽雅,金宏义.氨氯地平联合复方阿米洛利或替米沙坦对高血压患者降压疗效的相关临床因素分析[J].中国临床药理学与治疗学,2010,15(11):1273-1278. 被引量:6
  • 10Sica DA. Pharmacotherapy review:calcium channel blockers[ J]. J Clin Hypertens, 2006 ; 8:53 - 56.

二级参考文献43

  • 1金蜀蓉,齐云,任渝江.2000年~2003年长江流域6城市抗高血压药利用分析[J].中国药房,2005,16(8):597-601. 被引量:3
  • 2卫生部心血管病防治研究中心.中国心血管病报告2006.北京:中国大百科全书出版社,2007.
  • 3Liu L, Zhang Y, Liu G, et al. FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long- term placebo-controlled trial in Chinese hypertensive patients. J Hypertens, 2005,23 : 2157-2572.
  • 4Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004,363:2022-2031.
  • 5Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet ,2003,361 : 1149-1158.
  • 6Weber MA, Bakris GL, Dahlof B, et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press ,2007,16 : 13-19.
  • 7Wang JG, Li Y, Franklin SS, et al. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers : a quantitative overview. Hypertension, 2007,50 : 181 - 188.
  • 8Makino H, Haneda M, Babazono T, et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes : a post-hoc analysis of The Incipient to Overt: Angiotensin Ⅱ Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res,2008,31:657-664.
  • 9Sharma A, Bagchi A, Kinagi SB, et al. Results of a comparative, phase Ⅲ, 12-week, muhicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed- dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage Ⅱ hypertension. Clin Ther, 2007,29 : 2667 -2676.
  • 10Chrysant SG. Amlodipine/ARB fixed-dose combinations for the treatment of hypertension : focus on amlodipine/olmesartan combination. Drugs Today (Barc) ,2008,44:443-453.

共引文献106

同被引文献160

引证文献11

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部